AXL and mucosal melanoma: Treatment of the EGFR‐expressing melanoma cell line with anti‐EGFR antibody—cetuximab reduced the invasive capacity of the cells, but did not alter cell viability or growth,43 while cabozantinib, an inhibitor of tyrosine kinases including MET, VEGF (vascular endothelial growth factor) and AXL (tyrosine‐protein kinase receptor UFO), led to longer progression‐free survival and reduction in tumour size in the majority of patients with uveal, cutaneous and mucosal melanoma.46, 47